Skip to content

Drug interactions

Lonafarnib + Pazopanib

Severity: Moderate

Lonafarnib and Pazopanib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lonafarnib is a sensitive CYP3A substrate, and pazopanib is a weak CYP3A4 inhibitor that may raise its levels. Lonafarnib can cause gastrointestinal and other toxicity, and its effect on QT is not well defined.

What this interaction means in plain words

Lonafarnib and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Lonafarnib belongs to Miscellaneous; Pazopanib belongs to Oncology.

Evidence level: Low

Why it happens

Weak inhibition of CYP3A4 by pazopanib reducing lonafarnib metabolism.

What to do

Avoid if possible. If used, keep lonafarnib at the starting dose and monitor for arrhythmia symptoms, gastrointestinal toxicity and liver tests.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Lonafarnib and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Lonafarnib with Pazopanib?

MediHelp rates the interaction as moderate. Lonafarnib and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lonafarnib is a sensitive CYP3A substrate, and pazopanib is a weak CYP3A4 inhibitor that may raise its levels. Lonafarnib can cause gastrointestinal and other toxicity, and its effect on QT is not well defined.

How serious is the interaction between Lonafarnib and Pazopanib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible. If used, keep lonafarnib at the starting dose and monitor for arrhythmia symptoms, gastrointestinal toxicity and liver tests.

What other medicines interact with Pazopanib?

MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in